Telavancin: a new lipoglycopeptide with multiple mechanisms of action

References

• Griffith RS. Introduction to vancomycin. Rev. Infect. Dis.3(Suppl.), S200–S204 (1981).
   PubMedGoogle Scholar
• Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellman WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin. Proc.31, 564–582 (1956).
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol.4, 471–478 (2004).
   PubMed Web of Science ®Google Scholar
• Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother.42, 1303–1304 (1998).
   PubMed Web of Science ®Google Scholar
• Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents16(Suppl. 1), S31–S34 (2000).
   PubMedGoogle Scholar
• Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42, 2398–2402 (2004).
   PubMed Web of Science ®Google Scholar
• Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother.34, 1227–1231 (1990).
   PubMed Web of Science ®Google Scholar
• Woods CW, Cheng AC, Fowler VG Jr et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis.38, 1188–1191 (2004).
   PubMed Web of Science ®Google Scholar
• Leadbetter MR, Adams SM, Bazzini B et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo)57, 326–336 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother.48, 2149–2152 (2004).
   PubMed Web of Science ®Google Scholar
• King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother.53, 797–803 (2004).
   PubMed Web of Science ®Google Scholar
• Hegde SS, Reyes N, Wiens T et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother.48, 3043–3050 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother.49, 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST-2 study. Antimicrob. Agents Chemother.50, 862–867 (2006).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O’Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis.40, 1601–1607 (2005).
   PubMed Web of Science ®Google Scholar
• Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg. Med. Chem. Lett.13, 4165–4168 (2003).
   PubMed Web of Science ®Google Scholar
• Higgins DL, Chang R, Debabov DV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49, 1127–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Kaniga K, Blosser RS, Karlowsky JA, Sahm DF. In vitro activity of telavancin (TD-6424) against Bacillus anthracis. 44th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA. 30 October – 2 November (2004) (Abstract E-2010).
   Google Scholar
• Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother.47(11), 3602–3604 (2003).
   PubMed Web of Science ®Google Scholar
• Draghi DC, Jones ME, Thornsberry C, Flamm RK, Sahm DF. Telavancin activity against current and diverse Staphylococcus aureus populations. 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA 16–19 December (2005).
   Google Scholar
• Draghi DC, Jones ME, Flamm RK, Thornsberry C, Sahm DF. Telavancin activity against current and diverse populations of enterococci and Streptococcus pneumoniae. In: 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA 16–19 December (2005).
   Google Scholar
• Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.58, 338–343 (2006).
   PubMed Web of Science ®Google Scholar
• Finegold SM, Bolanos M, Summanen P, Molitoris DR. In vitro activity of telavancin and six comparator agents against 460 anaerobic bacteria. 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA 16–19 December (2005).
   Google Scholar
• Eliopoulos GM, Wennersten CB, Sakoulas G, Moellering RC Jr. In vitro bactericidal activity of telavancin against S. aureus with relative tolerance to vancomycin. 44th Annual International Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA 30 October – 2 November (2004).
   Google Scholar
• Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother.49, 3163–3165 (2005).
   PubMed Web of Science ®Google Scholar
• Krause K, Debabov D, Pace J, Kaniga K. Low frequency of spontaneous resistance to TD-6424 and delayed resistance selection in vitro among staphylococci and enterococci. 43rd Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Chicago, IL, USA 14–17 September (2003).
   Google Scholar
• Krause K, Benton BM, Higgins DL et al. Telavancin possesses low potential for resistant mutant selection in serial passage studies of Staphylococcus aureus and enterococci. 15th European Congress of Clinical Microbiology & Infectious Diseases. Copenhagen, Denmark, 2–5 April (2005).
   Google Scholar
• Pace J, Judice K, Hegde SS et al. Activity of TD-6424 against methicillin-resistant and -susceptible Gram-positive bacteria. 8th International Symposium on Staphylococci & Staphylococcal Infections. Regensburg, Germany (2002).
   Google Scholar
• Debabov D, Pace J, Nodwell M et al. TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, acts through a unique dual mode of action. 43rd Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Chicago, IL, USA 14–17 September (2003).
   Google Scholar
• Barriere S, Shaw JP, Seroogy J et al. Pharmacokinetic disposition and serum bactericidal activity following intravenous infusion of single and multiple ascending doses of TD-6424 in healthy male subjects. 13th European Congress of Clinical Microbiology & Infectious Diseases. Glasgow, UK 10–13 May (2003).
   Google Scholar
• Duchin K, Shaw JP, Spencer E et al. Single dose pharmacokinetics of telavancin in healthy elderly subjects. 14th European Congress of Clinical Microbiology & Infectious Diseases. Prague, Czech Republic 1–4 May (2004).
   Google Scholar
• Duchin K, Shaw JP, Seroogy J, Barriere S, Novack R. Effect of hemodialysis on single dose pharmacokinetics of telavancin. 15th European Congress of Clinical Microbiology & Infectious Diseases. Copenhagen, Denmark 2–5 April (2005).
   Google Scholar
• Duchin K, Shaw JP, Spencer E et al. Single dose pharmacokinetics of telavancin in subjects with renal dysfunction. 14th European Congress of Clinical Microbiology & Infectious Diseases. Prague, Czech Republic 1–4 May (2004).
   Google Scholar
• Sun HK, Duchin K, Nightingale CH et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother.50, 788–790 (2006).
   PubMed Web of Science ®Google Scholar
• Gotfried M, Duchin K, Shaw JP et al. Telavancin penetrates well into human pulmonary epithelial lining fluid and alveolar macrophages and is unaffected by pulmonary surfactant. 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy. Washington DC, USA, 16–19 December (2005).
   Google Scholar
• Stucki A, Gerber P, Acosta F et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob. Agents Chemother.50, 770–773 (2006).
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Kaniga K et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.49, 4344–4346 (2005).
   PubMed Web of Science ®Google Scholar
• Reyes N, Skinner R, Benton BM et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.58, 462–465 (2006).
   PubMed Web of Science ®Google Scholar
• Gander S, Kinnaird A, Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother.56, 337–343 (2005).
   PubMed Web of Science ®Google Scholar
• Barriere S, Genter F, Spencer E et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol.44, 689–695 (2004).
   PubMed Web of Science ®Google Scholar